[Availability of NMP22 (nuclear matrix protein 22) for the diagnosis of urothelial cancer].
We evaluated the availability of NMP22 for the diagnosis of urothelial cancer. Of 154 patients with gross hematuria or microscopic hematuria, 14 patients with bladder cancer and 4 patients with upper urothelial cancer were detected. Of 73 patients continued to be followed for urothelial cancers, 11 patients with bladder cancer were detected. NMP22 was not available when a large number of RBC was present in urine. Also, NMP22 was significantly higher in patients with urothelial cancers. Interpretation of the ROC curve indicated an optimal cutoff value of 9.2 u/ml. Using 9.2 u/ml as a cutoff, the sensitivity and specificity were, respectively 87.0% and 64.0% in patients with hematuria, and 81.8% and 78.7% in patients with a history of TCC. This indicated that when NMP22 was used for the diagnosis of urothelial cancers, 12.0 u/ml, the value recommended as a cutoff in Japan, might be too high to differentiate patients with urothelial cancers.
Akagashi
K
K
Sanjukai Hospital.
Tanda
H
H
Kato
S
S
Ohnishi
S
S
Nakajima
H
H
Nanbu
A
A
Nitta
T
T
Koroku
M
M
D014408:Biomarkers, Tumor / Q000652:urine*; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000175:diagnosis; D007682:Kidney Pelvis; D008297:Male; D009687:Nuclear Proteins / Q000652:urine*; D011237:Predictive Value of Tests; D012680:Sensitivity and Specificity; D014516:Ureteral Neoplasms / Q000175:diagnosis; D001749:Urinary Bladder Neoplasms / Q000175:diagnosis; D014556:Urine / Q000166:cytology; D014571:Urologic Neoplasms / Q000175:diagnosis*
D014408:Biomarkers, Tumor; D009687:Nuclear Proteins; C100379:nuclear matrix protein 22